Ability Announces Pricing of $10 Million Offering
TEL AVIV, ISRAEL, Nov. 23, 2018 (GLOBE NEWSWIRE) — Ability Inc. (Nasdaq: ABIL) (TASE: ABIL) (“Ability” or the “Company”), which […]
Aleafia Closes Transactions with Serruya Private Equity
Transactions Positions Aleafia as Major Supplier, Retailer of Adult-use Cannabis TORONTO, Nov. 23, 2018 (GLOBE NEWSWIRE) — Aleafia Health Inc. […]
TSX News -
Precision Drilling Confirms Its Offer; Strongly Encourages Trinidad Drilling Shareholders Not to Tender to Ensign Offer and to Vote for Value Creating Combination With Precision
This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For important information with respect […]
Aleafia to Release Q3 Results on November 26
TORONTO, Nov. 23, 2018 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), […]
Nordic American Offshore Ltd. (NYSE: NAO) Contemplated offshore project.
Hamilton, Bermuda, November 23, 2018 Dear Shareholders, The contemplated business combination, involving NAO and a group in Eastern Canada (Horizon […]
BLOCK LISTING SIX MONTHLY RETURN
BLOCK LISTING SIX MONTHLY RETURN November 23, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) Name of applicant: Shire plc […]
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with […]
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
LUXTURNA is first gene therapy for a genetic disease approved in both the U.S. and EU LUXTURNA is first and […]
